ADAM12 abrogation alters immune cell infiltration and improves response to checkpoint blockade therapy in the T11 murine model of triple-negative breast cancer

References

• Derakhshan F, Reis-Filho JS. Pathogenesis of triple-negative breast cancer. Annu Rev Pathol. 2022;17:181–16. doi:10.1146/annurev-pathol-042420-093238.
   PubMed Web of Science ®Google Scholar
• Zong Y, Pegram M. Research advances and new challenges in overcoming triple-negative breast cancer. Cancer Drug Resist. 2021;4:517–542. doi:10.20517/cdr.2021.04.
   PubMedGoogle Scholar
• Sharma P, Siddiqui BA, Anandhan S, Yadav SS, Subudhi SK, Gao J, Goswami S, Allison JP. The next decade of immune checkpoint therapy. Cancer Discov. 2021;11:838–857. doi:10.1158/2159-8290.CD-20-1680.
   PubMed Web of Science ®Google Scholar
• Emens LA. Immunotherapy in triple-negative breast cancer. Cancer J. 2021;27(1):59–66. doi:10.1097/PPO.0000000000000497.
   PubMed Web of Science ®Google Scholar
• Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Dieras V, Hegg R, Im S-A, Shaw Wright G, et al. Investigators IMT. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108–2121. doi:10.1056/NEJMoa1809615.
   PubMed Web of Science ®Google Scholar
• Adams S, Dieras V, Barrios CH, Winer EP, Schneeweiss A, Iwata H, Loi S, Patel S, Henschel V, Chui SY, et al. Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer. Ann Oncol. 2020;31(5):582–589. doi:10.1016/j.annonc.2020.02.003.
   PubMed Web of Science ®Google Scholar
• Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im S-A, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Holgado E, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396(10265):1817–1828. doi:10.1016/S0140-6736(20)32531-9.
   PubMed Web of Science ®Google Scholar
• Schmid P, Cortes J, Pusztai L, McArthur H, Kummel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, et al. KEYNOTE-522 Investigators. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810–821. doi:10.1056/NEJMoa1910549.
   PubMed Web of Science ®Google Scholar
• Mittendorf EA, Zhang H, Barrios CH, Saji S, Jung KH, Hegg R, Koehler A, Sohn J, Iwata H, Telli ML, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet. 2020;396(10257):1090–1100. doi:10.1016/S0140-6736(20)31953-X.
   PubMed Web of Science ®Google Scholar
• Brown LC, Loi S. Immune checkpoint inhibition in the treatment of early stage triple negative breast cancer: 2021 update. Breast. 2022;62(1):S29–S33. doi:10.1016/j.breast.2021.12.018.
   PubMedGoogle Scholar
• Kalbasi A, Ribas A. Tumour-intrinsic resistance to immune checkpoint blockade. Nat Rev Immunol. 2020;20:25–39. doi:10.1038/s41577-019-0218-4.
   PubMed Web of Science ®Google Scholar
• Hanna A, Balko JM. Breast cancer resistance mechanisms: challenges to immunotherapy. Breast Cancer Res Treat. 2021;190:5–17. doi:10.1007/s10549-021-06337-x.
   PubMed Web of Science ®Google Scholar
• Prat A, Adamo B, Cheang MC, Anders CK, Carey LA, Perou CM. Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist. 2013;18:123–133. doi:10.1634/theoncologist.2012-0397.
   PubMed Web of Science ®Google Scholar
• Lehmann BD, Jovanovic B, Chen X, Estrada MV, Johnson KN, Shyr Y, Moses HL, Sanders ME, Pietenpol JA. Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS One. 2016;11:e0157368. doi:10.1371/journal.pone.0157368.
   PubMed Web of Science ®Google Scholar
• Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010;12:R68.3096954. doi:10.1186/bcr2635.
   PubMed Web of Science ®Google Scholar
• Pommier RM, Sanlaville A, Tonon L, Kielbassa J, Thomas E, Ferrari A, Sertier AS, Hollande F, Martinez P, Tissier A, et al. Comprehensive characterization of claudin-low breast tumors reflects the impact of the cell-of-origin on cancer evolution. Nat Commun. 2020;11:3431. doi:10.1038/s41467-020-17249-7.
   PubMed Web of Science ®Google Scholar
• Fougner C, Bergholtz H, Norum JH, Sorlie T. Re-definition of claudin-low as a breast cancer phenotype. Nat Commun. 2020;11:1787. doi:10.1038/s41467-020-15574-5.
   PubMed Web of Science ®Google Scholar
• Kim IS, Gao Y, Welte T, Wang H, Liu J, Janghorban M, Sheng K, Niu Y, Goldstein A, Zhao N, et al. Immuno-subtyping of breast cancer reveals distinct myeloid cell profiles and immunotherapy resistance mechanisms. Nat Cell Biol. 2019;21:1113–1126. doi:10.1038/s41556-019-0373-7.
   PubMed Web of Science ®Google Scholar
• Taylor NA, Vick SC, Iglesia MD, Brickey WJ, Midkiff BR, McKinnon KP, Reisdorf S, Anders CK, Carey LA, Parker JS, et al. Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer. J Clin Invest. 2017;127:3472–3483. doi:10.1172/JCI90499.
   PubMed Web of Science ®Google Scholar
• Dongre A, Rashidian M, Reinhardt F, Bagnato A, Keckesova Z, Ploegh HL, Weinberg RA. Epithelial-to-mesenchymal transition contributes to immunosuppression in breast carcinomas. Cancer Res. 2017;77:3982–3989. doi:10.1158/0008-5472.CAN-16-3292.
   PubMed Web of Science ®Google Scholar
• Dongre A, Rashidian M, Eaton EN, Reinhardt F, Thiru P, Zagorulya M, Nepal S, Banaz T, Martner A, Spranger S, et al. Direct and indirect regulators of epithelial-mesenchymal transition-mediated immunosuppression in breast carcinomas. Cancer Discov. 2021;11:1286–1305. doi:10.1158/2159-8290.CD-20-0603.
   PubMed Web of Science ®Google Scholar
• Singh S, Zhang XHF, Rosen JM. Time is a great healer-targeting myeloid cells in the tumor immune microenvironment to improve triple-negative breast cancer outcomes. Cells. 2020;10:11. doi:10.3390/cells10010011.
   PubMed Web of Science ®Google Scholar
• Taki M, Abiko K, Ukita M, Murakami R, Yamanoi K, Yamaguchi K, Hamanishi J, Baba T, Matsumura N, Mandai M. Tumor immune microenvironment during epithelial-mesenchymal transition. Clin Cancer Res. 2021;27:4669–4679. doi:10.1158/1078-0432.CCR-20-4459.
   PubMed Web of Science ®Google Scholar
• Kolb HR, Borcherding N, Zhang W. Understanding and targeting human cancer regulatory T cells to improve therapy. Adv Exp Med Biol. 2021;1278:229–256.
   PubMed Web of Science ®Google Scholar
• Seegar TC, Blacklow SC. Domain integration of ADAM family proteins: emerging themes from structural studies. Exp Biol Med (Maywood). 2019;244:1510–1519. doi:10.1177/1535370219865901.
   PubMed Web of Science ®Google Scholar
• Schumacher N, Rose-John S, Schmidt-Arras D. ADAM-mediated signalling pathways in gastrointestinal cancer formation. Int J Mol Sci. 2020;21:5133. doi:10.3390/ijms21145133.
   PubMed Web of Science ®Google Scholar
• Theret N, Bouezzedine F, Azar F, Diab-Assaf M, Legagneux V. ADAM and ADAMTS proteins, new players in the regulation of hepatocellular carcinoma microenvironment. Cancers (Basel). 2021;13:1563. doi:10.3390/cancers13071563.
   PubMed Web of Science ®Google Scholar
• Lambrecht BN, Vanderkerken M, Hammad H. The emerging role of ADAM metalloproteinases in immunity. Nat Rev Immunol. 2018;18:745–758. doi:10.1038/s41577-018-0068-5.
   PubMed Web of Science ®Google Scholar
• Mortier A, Van Damme J, Proost P. Regulation of chemokine activity by posttranslational modification. Pharmacol Ther. 2008;120:197–217. doi:10.1016/j.pharmthera.2008.08.006.
   PubMed Web of Science ®Google Scholar
• Bronger H, Magdolen V, Goettig P, Dreyer T. Proteolytic chemokine cleavage as a regulator of lymphocytic infiltration in solid tumors. Cancer Metastasis Rev. 2019;38:417–430. doi:10.1007/s10555-019-09807-3.
   PubMed Web of Science ®Google Scholar
• Cecchinato V, Uguccioni M. Insight on the regulation of chemokine activities. J Leukoc Biol. 2018;104:295–300. doi:10.1002/JLB.3MR0118-014R.
   PubMed Web of Science ®Google Scholar
• Saw S, Weiss A, Khokha R, Waterhouse PD. Metalloproteases: on the watch in the hematopoietic niche. Trends Immunol. 2019;40:1053–1070. doi:10.1016/j.it.2019.09.006.
   PubMed Web of Science ®Google Scholar
• Nyren-Erickson EK, Jones JM, Srivastava DK, Mallik S. A disintegrin and metalloproteinase-12 (ADAM12): function, roles in disease progression, and clinical implications. Biochim Biophys Acta. 2013;1830:4445–4455. doi:10.1016/j.bbagen.2013.05.011.
   PubMed Web of Science ®Google Scholar
• Kveiborg M, Albrechtsen R, Couchman JR, Wewer UM. Cellular roles of ADAM12 in health and disease. Int J Biochem Cell Biol. 2008;40:1685–1702. doi:10.1016/j.biocel.2008.01.025.
   PubMed Web of Science ®Google Scholar
• Jerry DJ, Kittrell FS, Kuperwasser C, Laucirica R, Dickinson ES, Bonilla PJ, Butel JS, Medina D. A mammary-specific model demonstrates the role of the p53 tumor suppressor gene in tumor development. Oncogene. 2000;19(8):1052–1058. doi:10.1038/sj.onc.1203270.
   PubMed Web of Science ®Google Scholar
• Herschkowitz JI, Zhao W, Zhang M, Usary J, Murrow G, Edwards D, Knezevic J, Greene SB, Darr D, Troester MA, et al. Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells. Proc Natl Acad Sci USA. 2012;109(8):2778–2783. doi:10.1073/pnas.1018862108.
   PubMed Web of Science ®Google Scholar
• Pfefferle AD, Herschkowitz JI, Usary J, Harrell JC, Spike BT, Adams JR, Torres-Arzayus MI, Brown M, Egan SE, Wahl GM, et al. Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts. Genome Biol. 2013;14(11):R125. doi:10.1186/gb-2013-14-11-r125.
   PubMed Web of Science ®Google Scholar
• Hollern DP, Xu N, Thennavan A, Glodowski C, Garcia-Recio S, Mott KR, He X, Garay JP, Carey-Ewend K, Marron D, et al. B cells and T follicular helper cells mediate response to checkpoint inhibitors in high mutation burden mouse models of breast cancer. Cell. 2019;179(5):1191–1206. doi:10.1016/j.cell.2019.10.028.
   PubMed Web of Science ®Google Scholar
• Duhachek-Muggy S, Qi Y, Wise R, Alyahya L, Li H, Hodge J, Zolkiewska A. Metalloprotease-disintegrin ADAM12 actively promotes the stem cell-like phenotype in claudin-low breast cancer. Mol Cancer. 2017;16(1):32. doi:10.1186/s12943-017-0599-6.
   PubMedGoogle Scholar
• Li H, Duhachek-Muggy S, Dubnicka S, Zolkiewska A. Metalloproteinase-disintegrin ADAM12 is associated with a breast tumor-initiating cell phenotype. Breast Cancer Res Treat. 2013;139(3):691–703. doi:10.1007/s10549-013-2602-2.
   PubMed Web of Science ®Google Scholar
• Wang R, Godet I, Yang Y, Salman S, Lu H, Lyu Y, Zuo Q, Wang Y, Zhu Y, Chen C, et al. Hypoxia-inducible factor-dependent ADAM12 expression mediates breast cancer invasion and metastasis. Proc Natl Acad Sci USA. 2021;118(19):e2020490118. doi:10.1073/pnas.2020490118.
   PubMed Web of Science ®Google Scholar
• Diaz B, Yuen A, Iizuka S, Higashiyama S, Courtneidge SA. Notch increases the shedding of HB-EGF by ADAM12 to potentiate invadopodia formation in hypoxia. J Cell Biol. 2013;201(2):279–292. doi:10.1083/jcb.201209151.
   PubMed Web of Science ®Google Scholar
• Le Pabic H. ADAM12 in human liver cancers: TGF-β-regulated expression in stellate cells is associated with matrix remodeling. Hepatology. 2003;37(5):1056–1066. doi:10.1053/jhep.2003.50205.
   PubMed Web of Science ®Google Scholar
• Li H, Solomon E, Duhachek Muggy S, Sun D, Zolkiewska A. Metalloprotease-disintegrin ADAM12 expression is regulated by Notch signaling via microRNA-29. J Biol Chem. 2011;286(24):21500–21510. doi:10.1074/jbc.M110.207951.
   PubMed Web of Science ®Google Scholar
• Atfi A, Dumont E, Colland F, Bonnier D, A A, Prunier C, Ferrand N, Clement B, Wewer UM, Theret N. The disintegrin and metalloproteinase ADAM12 contributes to TGF-β signaling through interaction with the type II receptor. J Cell Biol. 2007;178(2):201–208. doi:10.1083/jcb.200612046.
   PubMed Web of Science ®Google Scholar
• Dyczynska E, Sun D, Yi H, Sehara-Fujisawa A, Blobel CP, Zolkiewska A. Proteolytic processing of Delta-like 1 by ADAM proteases. J Biol Chem. 2007;282(1):436–444. doi:10.1074/jbc.M605451200.
   PubMed Web of Science ®Google Scholar
• Kang Q, Cao Y, Zolkiewska A. Metalloprotease–disintegrin ADAM 12 binds to the SH3 domain of Src and activates Src tyrosine kinase in C2C12 cells. Biochem J. 2000;352(3):883–892. doi:10.1042/bj3520883.
   PubMed Web of Science ®Google Scholar
• Dyczynska E, Syta E, Sun D, Zolkiewska A. Breast cancer-associated mutations in metalloprotease disintegrin ADAM12 interfere with the intracellular trafficking and processing of the protein. Int J Cancer. 2008;122(11):2634–2640. doi:10.1002/ijc.23405.
   PubMed Web of Science ®Google Scholar
• Curtis C, Shah SP, Chin S-F, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486(7403):346–352. doi:10.1038/nature10983.
   PubMed Web of Science ®Google Scholar
• Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–404. doi:10.1158/2159-8290.CD-12-0095.
   PubMed Web of Science ®Google Scholar
• Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Science Signaling. 2013;6(269):l1. doi:10.1126/scisignal.2004088.
   Web of Science ®Google Scholar
• Solomon E, Li H, Duhachek Muggy S, Syta E, Zolkiewska A. The role of SnoN in transforming growth factor β1-induced expression of metalloprotease-disintegrin ADAM12. J Biol Chem. 2010;285(29):21969–21977. doi:10.1074/jbc.M110.133314.
   PubMed Web of Science ®Google Scholar
• Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, Chaleff S, Kotb M, Gillies SD, King M, Mangada J, et al. Human lymphoid and myeloid cell development in NOD/LtSz- scid IL2R γnullMice engrafted with mobilized human hemopoietic stem cells. J Immunol. 2005;174(10):6477–6489. doi:10.4049/jimmunol.174.10.6477.
   PubMed Web of Science ®Google Scholar
• Veglia F, Sanseviero E, Gabrilovich DI. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol. 2021;21(8):485–498. doi:10.1038/s41577-020-00490-y.
   PubMed Web of Science ®Google Scholar
• Liu Y, Chen K, Wang C, Gong W, Yoshimura T, Liu M, Wang JM. Cell surface receptor FPR2 promotes antitumor host defense by limiting M2 polarization of macrophages. Cancer Res. 2013;73(2):550–560. doi:10.1158/0008-5472.CAN-12-2290.
   PubMed Web of Science ®Google Scholar
• Cao Y, Kang Q, Zhao Z, Zolkiewska A. Intracellular processing of metalloprotease disintegrin ADAM12. J Biol Chem. 2002;277(29):26403–26411. doi:10.1074/jbc.M110814200.
   PubMed Web of Science ®Google Scholar
• Luther SA, Bidgol A, Hargreaves DC, Schmidt A, Xu Y, Paniyadi J, Matloubian M, Cyster JG. Differing activities of homeostatic chemokines CCL19, CCL21, and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis. J Immunol. 2002;169(1):424–433. doi:10.4049/jimmunol.169.1.424.
   PubMed Web of Science ®Google Scholar
• Schumacher TN, Thommen DS. Tertiary lymphoid structures in cancer. Science. 2022;375(6576):eabf9419. doi:10.1126/science.abf9419.
   PubMed Web of Science ®Google Scholar
• Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M, de Wind A, Ravoet M, Le Buanec H, Sibille C, Manfouo-Foutsop G, et al. CD4+ follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest. 2013;123(7):2873–2892. doi:10.1172/JCI67428.
   PubMed Web of Science ®Google Scholar
• Danaher P, Warren S, Dennis L, D’Amico L, White A, Disis ML, Geller MA, Odunsi K, Beechem J, Fling SP. Gene expression markers of tumor infiltrating leukocytes. J Immunother Cancer. 2017;5(1):18. doi:10.1186/s40425-017-0215-8.
   PubMed Web of Science ®Google Scholar
• Iglesia MD, Vincent BG, Parker JS, Hoadley KA, Carey LA, Perou CM, Serody JS. Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer. Clin Cancer Res. 2014;20(14):3818–3829. doi:10.1158/1078-0432.CCR-13-3368.
   PubMed Web of Science ®Google Scholar
• Crotty S. A brief history of T cell help to B cells. Nat Rev Immunol. 2015;15(3):185–189. doi:10.1038/nri3803.
   PubMed Web of Science ®Google Scholar
• Cassetta L, Fragkogianni S, Sims AH, Swierczak A, Forrester LM, Zhang H, Soong DYH, Cotechini T, Anur P, Lin EY, et al. Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming, biomarkers, and therapeutic targets. Cancer Cell. 2019;35(4):588–602. doi:10.1016/j.ccell.2019.02.009.
   PubMed Web of Science ®Google Scholar
• Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, Yizhak K, Sade-Feldman M, Blando J, Han G, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020;577(7791):549–555. doi:10.1038/s41586-019-1922-8.
   PubMed Web of Science ®Google Scholar
• Petitprez F, de Reynies A, Keung EZ, Chen TW, Sun C-M, Calderaro J, Jeng Y-M, Hsiao L-P, Lacroix L, Bougouin A, et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature. 2020;577(7791):556–560. doi:10.1038/s41586-019-1906-8.
   PubMed Web of Science ®Google Scholar
• Cabrita R, Lauss M, Sanna A, Donia M, Skaarup Larsen M, Mitra S, Johansson I, Phung B, Harbst K, Vallon-Christersson J, et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. 2020;577(7791):561–565. doi:10.1038/s41586-019-1914-8.
   PubMed Web of Science ®Google Scholar
• Cui C, Wang J, Fagerberg E, Chen P-M, Connolly KA, Damo M, Cheung JF, Mao T, Askari AS, Chen S, et al. Neoantigen-driven B cell and CD4 T follicular helper cell collaboration promotes anti-tumor CD8 T cell responses. Cell. 2021;184(25):6101–6118. doi:10.1016/j.cell.2021.11.007.
   PubMed Web of Science ®Google Scholar
• Fridman WH, Petitprez F, Meylan M, Chen TW, Sun C-M, Roumenina LT, Sautes-Fridman C. B cells and cancer: to B or not to B? J Exp Med. 2021;218(1):e20200851. doi:10.1084/jem.20200851.
   PubMed Web of Science ®Google Scholar
• Laumont CM, Banville AC, Gilardi M, Hollern DP, Nelson BH. Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities. Nat Rev Cancer. 2022;22(7):414–430. doi:10.1038/s41568-022-00466-1.
   PubMed Web of Science ®Google Scholar
• Shalapour S, Karin M. The neglected brothers come of age: B cells and cancer. Semin Immunol. 2021;52:101479. doi:10.1016/j.smim.2021.101479.
   PubMed Web of Science ®Google Scholar
• Fridman WH, Meylan M, Petitprez F, Sun C-M, Italiano A, Sautes-Fridman C. B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome. Nat Rev Clin Oncol. 2022;19(7):441–457. doi:10.1038/s41571-022-00619-z.
   PubMed Web of Science ®Google Scholar
• Downs-Canner SM, Meier J, Vincent BG, Serody JS. B cell function in the tumor microenvironment. Annu Rev Immunol. 2022;40(1):169–193. doi:10.1146/annurev-immunol-101220-015603.
   PubMedGoogle Scholar
• Harris RJ, Cheung A, Ng JCF, Laddach R, Chenoweth AM, Crescioli S, Fittall M, Dominguez-Rodriguez D, Roberts J, Levi D, et al. Tumor-infiltrating B lymphocyte profiling identifies IgG-biased, clonally expanded prognostic phenotypes in triple-negative breast cancer. Cancer Res. 2021;81(16):4290–4304. doi:10.1158/0008-5472.CAN-20-3773.
   PubMed Web of Science ®Google Scholar
• Vick SC, Kolupaev OV, Perou CM, Serody JS. Anti–PD-1 checkpoint therapy can promote the function and survival of regulatory T cells. J Immunol. 2021;207(10):2598–2607. doi:10.4049/jimmunol.2001334.
   PubMed Web of Science ®Google Scholar
• Shaul ME, Fridlender ZG. Tumour-associated neutrophils in patients with cancer. Nat Rev Clin Oncol. 2019;16(10):601–620. doi:10.1038/s41571-019-0222-4.
   PubMed Web of Science ®Google Scholar
• Jaillon S, Ponzetta A, Di Mitri D, Santoni A, Bonecchi R, Mantovani A. Neutrophil diversity and plasticity in tumour progression and therapy. Nat Rev Cancer. 2020;20(9):485–503. doi:10.1038/s41568-020-0281-y.
   PubMed Web of Science ®Google Scholar
• DeNardo DG, Ruffell B. Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol. 2019;19(6):369–382. doi:10.1038/s41577-019-0127-6.
   PubMed Web of Science ®Google Scholar
• Singh S, Lee N, Pedroza DA, Bado IL, Hamor C, Zhang L, Aguirre S, Hu J, Shen Y, Xu Y, et al. Chemotherapy coupled to macrophage inhibition induces T-cell and B-cell infiltration and durable regression in triple-negative breast cancer. Cancer Res. 2022;82(12):2281–2297. doi:10.1158/0008-5472.CAN-21-3714.
   PubMedGoogle Scholar
• McQuibban GA, Butler GS, Gong J-H, Bendall L, Power C, Clark-Lewis I, Overall CM. Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J Biol Chem. 2001;276(47):43503–43508. doi:10.1074/jbc.M107736200.
   PubMed Web of Science ®Google Scholar
• Janssens R, Struyf S, Proost P. The unique structural and functional features of CXCL12. Cell Mol Immunol. 2018;15(4):299–311. doi:10.1038/cmi.2017.107.
   PubMed Web of Science ®Google Scholar